Additionally, there is currently no agreement among animal studies regarding the specific HDAC isoforms that should be selectively inhibited to achieve the therapeutic effect and an adequate safety profile in neurons, so HDACi clinical trials are ongoing to assess their safety and efficacy in patients with NDD [237]. This evidence concerns the gene HDAC9 and Neurodevelopmental delay.